Horizon Pharma PLC (NASDAQ:HZNP) is off by 12.6% after the New York Times published an article detailing how Horizon's Duexis costs $1,500-per-month, yet is just a combination of the generic equivalents of Pepcid and Motrin, which cost no more than $40 and $20-per-month, respectively. The Times article further states that Horizon has increased the price of Duexis by a factor of ten since late 2011 and has done similar things with Vimovo, a similar type of generic combination drug that the company acquired in 2013. Investors are selling the stock because New York Times articles are more likely to draw regulatory scrutiny. Any type of drug price ceiling could send Horizon Pharma's 10.08 forward P/E higher.